Occurrence of relative bradycardia and relative tachycardia in individuals diagnosed with COVID-19

Aravind Natarajan,* Hao-Wei Su, and Conor Heneghan

Fitbit Research, 199 Fremont St, Fl #14, San Francisco, CA 94105

(Dated: January 28, 2022)

Abstract

Background:

The COVID-19 disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become one of the worst global pandemics of the century causing tremendous human and economic suffering worldwide. While considered a respiratory disease, COVID-19 is known to cause cardiac complications. Wearable devices are well equipped to measure heart rate continuously and their popularity makes them valuable devices in the field of digital health. In this article, we use Fitbit devices to examine resting heart rate from individuals diagnosed with COVID-19 ^a

Methods:

The Fitbit COVID-19 survey was conducted from May 2020 - June 2021. We collected resting heart rate data from 7,200 individuals (6,606 symptomatic, 594 asymptomatic) diagnosed with COVID-19 between March 2020 - December 2020, as well as from 463 individuals diagnosed with influenza between January 2020 - December 2020. Data from healthy individuals served as a control, in order to model the seasonal variation. We also computed heart rate variability and respiratory rate data for symptomatic COVID-19.

Findings:

Resting Heart Rate is elevated during COVID-19 symptom onset, with average peak increases relative to the baseline of $1.8\% \pm 0.1\%$ ($3.4\% \pm 0.2\%$) for females (males), where the quoted numbers are mean and standard error of the mean. After the initial peak, the resting heart rate decreased and reached a minimum on average ≈ 13 days after symptom onset. The minimum value relative to the baseline is more negative for females ($-1.75\% \pm 0.1\%$) compared to males ($0.08\% \pm 0.2\%$). The resting heart rate then increased, reaching a second peak on average ≈ 28 days from symptom onset, before falling back to the baseline ≈ 112 days from symptom onset. All estimates vary with disease severity.

Interpretation:

The resting heart rate is modified for several months following a COVID-19 diagnosis. Interestingly, this effect is seen with seasonal influenza also, although the bradycardia minimum and the second tachycardia peak are often more pronounced in the case of symptomatic COVID-19. By computing resting heart rate daily, wearable devices can contribute to monitoring wellness during recovery from COVID-19, and seasonal influenza.

2

Funding: A.N., H.-W.S., and C.H. are supported by Fitbit Research, Google LLC.

Research in Context:

Evidence before this study:

- We searched PubMed, Google, and Google Scholar for research articles published in
- ⁵ English up to Oct 31, 2021, using common search terms such as "bradycardia and COVID-
- 6 19", "cardiac complications and COVID-19", etc. Articles were also retrieved by searching
- ⁷ through citations of known literature. It is known that COVID-19 can cause cardiac com-
- 8 plications such as bradycardia and arrhythmias. Using data from commercially available
- 9 wearable devices, it has been shown previously that the resting heart is elevated during
- symptom onset, then decreases reaching a minimum, before rising again to attain a second
- peak, before finally returning to the baseline.

12 Added value of this study:

- We present results from the largest (to our knowledge) dataset considered to-date, involv-
- ing 7200 participants (6606 symptomatic and 594 asymptomatic) diagnosed with COVID-19.
- 15 We also present results from 463 individuals diagnosed with influenza. Our large dataset
- 16 allows us to perform more detailed examinations by age, disease severity, and sex. We also
- discuss the time evolution of heart rate variability and respiratory rate. The heart rate
- variability shows a similar time evolution as the resting heart rate but with opposite phase,
- while the respiratory rate decreases monotonously following the peak at symptom onset.

Implications of all the available evidence:

- The results presented in this work show that commercially available trackers and smart-
- 22 watches can help in monitoring heart health in the weeks and months following a COVID-19
- 23 diagnosis. An estimate of the amplitude of the bradycardia dip may provide information
- valuable to critical care.

20

25 I. INTRODUCTION

- Cardiac complications are known to be associated with the COVID-19 disease caused by
- the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)¹⁻⁸. Cardiac

^a This feature is not intended to diagnose or treat any medical condition and should not be relied on for any medical purposes. It is provided to Fitbit users to help manage well-being.

injury, heart failure, and arrhythmias have been recorded in patients diagnosed with COVID-19^{1,5,9,10}.

An unusual feature that is sometimes seen in patients diagnosed with COVID-19 is the 30 appearance of bradycardia, i.e. slow heart rate, or heart rate not increasing as expected 31 with body temperature^{11–14}. Amaratunga et al. ¹⁵ found bradycardia in a study of 4 patients 32 with confirmed COVID-19, with minimum pulse rates in the range 42-49 beats per minute. Amir et al. 16 reported 6 cases of bradycardia among patients diagnosed with COVID-19. with 4 patients developing complete atrioventricular block. Elikowski et al. 17 presented clinical data of 19 patients diagnosed with COVID-19 who exhibited sinus bradycardia, in some cases showing heart rates as low as 32 bpm during daily hours. Srinivasan et al. 18 discussed 6 cases of patients who were diagnosed with COVID-19 and admitted with normal sinus rhythm, and who subsequently developed sinus bradycardia with daytime heart rates ranging from 35-48 bpm. In a study of 97 patients with a non-severe presentation of COVID-19, Zhou et al. 19 found significant sinus bradycardia (below 50 bpm) in 7.2% of cases. Guo et al.²⁰ reported ventricular tachycardia (VT) or ventricular fibrillation (VF) in 11 out of 187 patients with confirmed COVID-19 and found that elevated levels of troponin T were correlated with VT/VF. Inflammatory damage due to cytokines has been suggested as a possible explanation for cardiac involvement with COVID-19^{17,21–23}.

Commercially available wearable devices have been shown to be useful in early detection of COVID-19 and for monitoring symptoms^{24–29}. Radin et al.³⁰ studied resting heart rate (henceforth RHR) data from Fitbit devices to investigate long term changes following symptom onset. RHR is typically elevated around symptom onset. We use the term "relative" to indicate that the RHR is elevated/decreased relative to the baseline value for that individual, although the RHR is not necessarily above/below the clinical threshold guideline³¹. They also found the RHR exhibits a dip which we refer to as transient relative bradycardia provided the RHR is below the baseline value. The RHR dip was followed by a second elevated RHR peak. They found that the RHR was elevated for up to 79 days from symptom onset.

In this article, we obtain results consistent with the findings of Radin et al., and expand upon existing work in a number of ways. We study a much larger sample size than previously considered. We investigate how the resting heart range changes, for male and female individuals, and for individuals with severe, mild or asymptomatic presentations of

COVID-19. We also consider individuals diagnosed with the seasonal influenza (henceforth "flu"). We tabulate the expected amplitudes of the maxima/minima, as well as the time taken to reach these maxima/minima, and the estimated widths of the peaks/troughs. We examine how these parameters vary with age, sex, and disease severity. We also study heart rate variability and respiratory rate and how these metrics vary with time.

55 II. METHODS

66

A. Survey Data

The Fitbit COVID-19 survey was conducted from May 21, 2020 to June 10, 2021, and 67 collected data from participants residing in the USA or Canada. Participants provided in-68 formation on whether they were diagnosed with COVID-19 or flu, as well as the test date, symptoms, and the start date of symptoms. Participants could optionally provide information about their age, sex, body mass index, and information on underlying conditions. Individuals diagnosed with COVID-19 also indicated the severity of the disease which could be (i) severe, indicating that they required hospitalization, (ii) mild, indicating that they recovered at home, or (iii) asymptomatic. The survey and associated marketing and recruitment materials were approved by an Institutional Review Board (Advarra). The participants provided electronic informed consent for their data to be used for research. In this study, 76 we consider data from Fitbit users who reported testing positive for COVID-19 in the date 77 range March 1 - Dec 31, 2020, as well as users who reported testing positive for flu in the 78 date range Jan 1 - Dec 31, 2020. There were 11,918 participants who tested positive for 79 COVID-19 (mean age = 40.8 yr, std. dev. = 12.4 yr, 79.0% female) in our dataset, and 865 participants who tested positive for flu (mean age = 41.7 yr, std. dev. = 13.3 yr, 81 78.2% female). We randomly select 1,000 users who did not report a positive test for either COVID-19 or flu as a control group (mean age = 45.3 yr, std. dev. = 13.9 yr, 71.6% female). Table I shows the prevalence of symptoms (self reported) for COVID-19 and flu, for male and female participants (for COVID-19, we also separate by disease severity). Some symptoms such as fatigue, headache and body ache are common for both COVID-19 and flu. By contrast, a decrease in taste and/or smell is more likely in the case of COVID-19 (72.6\% female, 59.8\% male) compared to flu (21.2\% female, 11.6\% male). Fever is more common with flu (81.3% female, 76.8% male) compared to COVID-19 (51.4% female, 58% male). Fig. 1 shows the distribution of positive cases for flu and COVID-19, where the horizontal axis is the test date, and only positive cases are shown. Cases of flu peaked in March 2020, while COVID-19 cases peaked much later.

B. RHR data

93

102

We measure the RHR from participants in our study, collected using Fitbit devices. The

"resting heart rate" as defined by Fitbit is the value closest to the heart rate measured when

lying down just before waking up in the morning³².

RHR is computed using heart rate data during sleep when sleep data is available, and

a proprietary algorithm is utilized to predict the RHR from the time series heart rate data

during sleep. If sleep data is unavailable, RHR is computed using wake time heart rate data, at times when no activity is detected. The RHR is also processed with a Kalman filter which

serves to smooth the waveform. Note that the RHR is not the minimum value of heart rate.

C. Time variation of the RHR data

Let D_0 be the date of symptom onset for symptomatic individuals (and the test date for asymptomatic individuals). Thus for symptomatic individuals, D_{-1} is one day prior to the appearance of symptoms, and D_{+1} is one day post appearance of symptoms. We computed the mean value $\langle RHR \rangle$ for each individual by averaging the RHR values from D_{-90} to D_{-15} . We discard data from participants who have fewer than 30 measurements in this time window. With this data sufficiency condition, our dataset contains 463 individuals with the flu, and 7200 individuals with COVID-19 (6606 symptomatic, 594 asymptomatic). We compute the fractional change in RHR ξ from days D_{-14} to D_{+180} as:

$$\xi(d) = \frac{RHR(d) - \langle RHR \rangle}{\langle RHR \rangle},\tag{1}$$

where d is a variable indicating day index.

Symptom	Mild (fem.)	Mild (male)	Severe (fem.)	Severe (male)	Flu (fem.)	Flu (male)
Fatigue	0.847	0.761	0.885	0.816	0.843	0.689
Headache	0.793	0.640	0.789	0.618	0.661	0.415
Decrease in taste/smell	0.727	0.598	0.701	0.592	0.211	0.116
Congestion	0.715	0.571	0.503	0.342	0.541	0.512
Body ache	0.689	0.666	0.793	0.684	0.818	0.677
Cough	0.652	0.627	0.784	0.730	0.731	0.616
Chills	0.532	0.557	0.713	0.632	0.734	0.604
Fever	0.501	0.563	0.749	0.796	0.813	0.768
Sore throat	0.498	0.385	0.418	0.342	0.560	0.378
Loss of appetite	0.472	0.345	0.701	0.638	0.440	0.293
Shortness of breath	0.432	0.347	0.871	0.836	0.396	0.299
Chest pain	0.401	0.284	0.687	0.533	0.334	0.244
Diarrhea	0.399	0.319	0.524	0.454	0.192	0.189
Neck pain	0.296	0.186	0.322	0.191	0.193	0.116
Hoarse voice	0.280	0.179	0.320	0.303	0.279	0.110
Eye pain	0.232	0.161	0.232	0.197	0.106	0.067
Stomach ache	0.225	0.115	0.290	0.118	0.130	0.104
Confusion	0.178	0.135	0.368	0.349	0.114	0.140
Vomiting	0.089	0.044	0.271	0.118	0.115	0.067
Rash	0.067	0.034	0.131	0.066	0.029	0.037
Swelling in fingers/toes	0.044	0.022	0.133	0.079	0.032	0.043

TABLE I. Prevalence of symptoms, for COVID-19 (mild/severe) and flu, for male and female participants.

D. Controlling for the seasonality of resting heart rate

112

The RHR has a known seasonal modulation. In a study of 200,000 individuals wearing Fitbit devices and residing in the United States, Quer et al.³³ found a change in the popu-




FIG. 1. Incidence of Flu (top) and COVID-19 (bottom) in the year 2020, from the Fitbit COVID-19 survey.

lation's average RHR by 2 beats per minute (bpm). In the Northern hemisphere, the RHR peaks in the first week of January and reaches its minimum at the end of July.

117

118

119

120

Since all participants in our study reside in the USA or Canada, we assume that they are subject to the same seasonal trends. We use the control group to estimate how RHR varies with the time of year, by applying Eq. 1 to obtain ξ_{control} as follows:

1. Randomly sample a date from the COVID-19 or flu distribution and set to D_0 (date

Symbol	Description
N	Sample size
$A_{ m t1}$	Amplitude of the first relative tachycardia peak
A_b	Amplitude of the relative bradycardia trough
$A_{ m t2}$	Amplitude of the second relative tachycardia peak
$T_{ m t1}$	Time from symptom onset to first relative tachycardia peak
T_b	Time from symptom onset to relative bradycardia trough
$T_{ m t2}$	Time from symptom onset to second relative tachycardia peak
$W_{ m t1}$	Full width at half maximum of first relative tachycardia peak
$W_{ m b}$	Full width at half minimum of relative bradycardia trough only if $A_b < 0$
$W_{ m t2}$	Full width at half maximum of second relative tachycardia peak

TABLE II. Description of parameters.

of symptom onset).

121

122

123

128

2. Compute $\xi_{\text{control}}(d)$ using Eq. 1 from the control group for dates d relative to D_0 .

We may then subtract out the seasonality to find the effect of illness on RHR:

$$\Delta \xi = \xi - \xi_{\text{control},\alpha},\tag{2}$$

where α may be flu or COVID-19. Note that ξ_{control} must be computed twice: once for the COVID-19 distribution, and once for the flu distribution. To compute $\Delta \xi(d)$ for a given individual, we would use the appropriate $\xi_{\text{control},\alpha}$ depending on whether the participant was diagnosed with flu or COVID-19.

E. Estimation of parameters

We estimate a number of parameters from the time variation of $\Delta \xi$. These are summarized in Table II. The waveforms for ξ and ξ_{control} are linearly interpolated with a step
size of 0.2 days. The waveforms are then smoothed with a Savitzky–Golay filter with a
window length of 7 days. We compute $\Delta \xi$ from the smoothed waveforms, and estimate the
peaks/troughs by means of a peak detection algorithm. We also report an estimated error
on the parameter values using the jackknife technique^{34,35}.

F. Heart Rate Variability and Respiratory Rate

Details on how Fitbit devices compute respiratory rate and heart rate variability have 136 been previously published^{28,36}. In this article, we consider RMSSD computed in 5 minute 137 windows between the hours of midnight and 6 am. The median of the measurements is then 138 reported. For the respiratory rate calculation, we first compute the power spectral density 139 of interbeat intervals in 5 minute windows between the hours of midnight and 7 am. The 140 measurements are then averaged, and the respiratory rate is estimated from the averaged 141 power spectral density. We subtract out the seasonality of the RMSSD and respiratory rate 142 in a similar manner to the RHR, with the addition of a median filter (with a period of 7 143 days). The median filter was necessary because the RMSSD and respiratory rate waveforms are not smoothed by a Kalman filter, and are hence noisier than the RHR.

G. Code

146

149

157

158

159

160

135

All computations are performed using standard Python libraries.

148 III. RESULTS

A. Change in RHR following a Flu / COVID-19 diagnosis

Fig. 2 shows the fractional change in RHR for flu and COVID-19, for symptomatic individuals. Subplot (a) compares ξ and ξ_{control} for flu, while subplot (b) compares ξ and ξ_{control} for COVID-19. The horizontal axis D_n is the date relative to the date when symptoms first appear (n < 0 are prior to symptom onset, while n > 0 are after symptom onset. D_0 is the date when symptoms first present). ξ and ξ_{control} are averaged over all individuals for a specific D_n . Subplot (c) shows $\Delta \xi$, i.e. the excess fractional change in RHR after the seasonal variation has been subtracted. From subplot (c), we infer the following:

- 1. The excess fractional change in RHR, i.e. $\Delta \xi$ is elevated on average during the onset of symptoms. $\Delta \xi$ reaches a peak value $A_{\rm t1}$ at a time $T_{\rm t1}$ days from the onset of symptoms. This is the first transient relative tachycardia.
 - 2. Following the peak, $\Delta \xi$ decreases, reaching a minimum value $A_{\rm b}$ at a time $T_{\rm b}$ days




FIG. 2. Fractional change in RHR (ξ), for individuals diagnosed with flu (a) and COVID-19 (b), along with the expected seasonal variation ($\xi_{\rm control}$). (c) shows the excess fractional change in RHR ($\Delta \xi$) for flu and COVID-19. The parameters shown in (d) are defined in Table II.

161

162

163

164

165

from the onset of symptoms. If $A_{\rm b} < 0$, we refer to the trough as transient relative bradycardia.

- 3. Following the minimum, $\Delta \xi$ increases again, reaching a second peak A_{t2} at a time T_{t2} days from symptom onset. This is the second transient relative tachycardia.
- 4. Past $T_{\rm t2}$, $\Delta \xi$ decreases and eventually falls to zero, indicating that the RHR variation

is no longer due to illness.

166

169

The parameters A_{t1} , A_{b} , A_{t2} , T_{t1} , T_{b} , T_{t2} , W_{t1} , W_{b} , and W_{t2} are marked in subplot (d), and described in Table II.




FIG. 3. Excess fractional change in RHR ($\Delta \xi$), variation with severity and sex: (a) shows $\Delta \xi$ for severe, mild, and asymptomatic COVID-19, as well as flu. (b) shows $\Delta \xi$ for male and female individuals diagnosed with flu. (c) and (d) show $\Delta \xi$ for male and female participants, for the cases for severe and mild COVID-19 respectively.

Fig. 3 shows the excess fractional change in RHR ($\Delta \xi$) for COVID-19 and flu, for varying

Disease	Sex	N	$A_{ m t1}$	$A_{ m b}$	$A_{ m t2}$
COVID-19	F	5183	1.78 ± 0.08	-1.75 ± 0.10	1.81±0.08
COVID-19	M	1411	3.39 ± 0.18	0.08 ± 0.18	2.80 ± 0.17
Flu	F	360	2.60 ± 0.32	-0.57 ± 0.33	0.96 ± 0.30
Flu	M	103	4.28 ± 0.67	0.66 ± 0.72	1.94 ± 0.58

TABLE III. Estimation of peak amplitudes. N is the sample size. Estimates are mean and jackknife standard error of the mean.

Age (yr)	Sex	N	$A_{ m t1}$	$A_{ m b}$	$A_{ m t2}$	$T_{ m t1}$	T_b	$T_{ m t2}^*$	$W_{ m t1}$	$W_{\rm b}$	$W_{ m t2}$
20-29	F	994	1.9	-2.7	1.6	2	11.4	25.8	5	8.8	32.8
30-39	F	1627	1.8	-2.1	1.7	2	11.6	27.4	5	9.4	33.2
40-49	F	1305	1.4	-1.8	1.6	1.8	12	27	4.8	10	35.6
50-59	F	842	2.3	-0.8	2.4	2.4	14.6	37.8	6	7.4	48
≥60	F	364	2	-1.6	2	2.6	15.6	38.6	7.6	6.8	53
20-29	M	178	3.5	-1.6	2.5	2.6	11.8	33.8	6.4	7	44
30-39	M	392	3.7	-0.4	2.7	2.4	14.2	27.6	6.8	3.2	55.6
40-49	M	370	3.4	-0.2	2.4	2.6	16.6	28.8	9.4	2	43.8
50-59	M	275	3	0.6	3.7	3	17	28.8	13.2	-	36
≥60	M	175	3.8	1	3.5	5.6	15.6	27.6	12.4	-	53.8

TABLE IV. Estimation of parameters, by age.

severity, and for male and female individuals. Subplot (a) shows the effect of severity on $\Delta \xi$. The magenta curve is plotted for severe cases (i.e cases that required hospitalization). The brown curve shows mild cases, while the green curve is plotted for asymptomatic cases. The blue curve shows $\Delta \xi$ for flu. The amplitudes of the two relative tachycardia peals A_{t1} and A_{t2} are much larger in the case of severe COVID-19. The bradycardia dip (A_b) is more pronounced in the case of mild COVID-19. The first relative tachycardia peak amplitude (A_{t1}) is larger for flu compared to mild or asymptomatic COVID-19, while the second

^{*} Values of T_{t2} are only approximate due to noise and the large width of the second relative tachycardia peak.

Severity	Sex	N	$A_{ m t1}$	$A_{\rm b}$	$A_{ m t2}$	$T_{ m t1}$	T_b	$T_{ m t2}^*$	$W_{ m t1}$	$W_{ m b}$	$W_{ m t2}$
Severe	F	221	4	-0.9	4.4	5	16.4	38.4	10	3.8	46.8
Severe	M	81	9.1	0.8	6.4	9.2	18.2	37.4	11.8	-	51.2
Mild	F	4943	1.7	-1.8	1.5	2	12.4	28.2	5.2	9.6	37
Mild	M	1326	3.3	0	2.7	2.8	15	28.2	7.8	-	41.4
Asymptomatic	F	452	0.7	-0.7	1.2	0	5	21.8	3.2	8.6	35.6
Asymptomatic	M	142	0.6	-0.7	0.8	1	8.8	27	5.8	5.4	8
Flu	F	360	2.6	-0.6	0.96	2.4	11	26.8	6.4	4.6	29.2
Flu	M	103	4.3	0.66	1.45	2.8	10.2	15.6	8.4	-	59.6

TABLE V. Estimation of parameters, by severity.

tachycardia peak is similar in the cases of flu and asymptomatic COVID-19. For the cases 177 of severe, mild, asymptomatic, and flu respectively, we find $\Delta \xi$ falls to zero approximately 178 118, 112, 79, and 71 days after the onset of symptoms (or test date for asymptomatic cases). 179 Subplot (b) shows the difference between male and female individuals who were diagnosed 180 with flu. Similar to the case of COVID-19, the peak amplitudes A_{t1} and A_{t2} are higher for 181 males compared to females. The trough amplitude A_b is lower for females. Subplots (c) and 182 (d) shows the variation of $\Delta \xi$ for male and female individuals, for severe and mild COVID-19 183 cases respectively. In both cases, the peak amplitudes A_{t1} and A_{t2} are higher for males, for 184 both severe and mild cases of COVID-19. The minimum amplitude $A_{\rm b}$ on the other hand is 185 lower in females than in males, and is more negative for mild cases of COVID-19 compared 186 to severe cases. 187

Table III shows the estimated values of the amplitudes for the RHR minimum (A_b) and the two maxima $(A_{t1} \text{ and } A_{t2})$, along with jackknife estimated standard errors. Table IV shows the estimated values of the various parameters, for female and male participants, and for different ages. Each peak/trough is characterized by 3 parameters: the amplitude, time from symptom onset, and full width at half maximum/minimum. The 2 relative tachycardia peaks are parameterized by (A_{t1}, T_{t1}, W_{t1}) and (A_{t2}, T_{t2}, W_{t2}) , while the minimum is parameterized by (A_b, T_b, W_b) . Note that W_b is only defined when $A_b < 0$ indicating relative

^{*} Values of T_{t2} are only approximate due to noise and the large width of the second relative tachycardia peak.




FIG. 4. Parameters describing the time evolution of the RHR, from Table V, for different age groups, for male (black) and female (red) individuals. Jackknife error bars represent the standard error of the mean. Subplot for T_{t2} is not shown.

bradycardia. Table V shows the estimated values of the parameters for male and female participants, for severe, mild, and asymptomatic COVID-19 presentations, as well as for flu. Fig. 4 shows the estimated mean values of these parameters for different age groups, for male (black) and female (red) individuals.




FIG. 5. (a) Fraction of individuals with $\Delta RHR \leq x$ in the relative bradycardia window (red points), where x is a threshold, compared to the fraction that could be expected due to chance (green points). (b) shows the fraction of individuals with $\Delta RHR \geq x$ in the relative tachycardia window (red points), compared to the fraction that could be expected due to chance (green points). ΔRHR is the excess RHR compared to the control window. Error bars show standard error of the mean.

B. Relative bradycardia and relative tachycardia

Let us now quantify the prevalence of relative bradycardia and relative tachycardia. To do
this, we define the following 4 windows each of which are 15 days long (starting and ending
dates inclusive, and D_0 is the date when symptoms present, only symptomatic individuals
included):

• "Control" window from D_{-45} to D_{-31} .

199

204

205

224

225

- Presumed "healthy" window from D_{-30} to D_{-16} .
- Presumed "relative bradycardia" window from D_{+7} to D_{+21} .
- Presumed "relative tachycardia" window from D_{+22} to D_{+36} .

The healthy and control windows are expected to contain data when participants are healthy. The RHR is averaged over each window, and we only consider participants who have 15 days of data in each window. Let ΔRHR_w be the difference between the RHR averaged over window w and the RHR averaged over the control window:

$$\Delta RHR_w = \langle RHR \rangle_w - \langle RHR \rangle_{\text{control}}.$$
 (3)

We compute the fraction of participants who have $\Delta RHR \leq x$ bpm, computed from the 212 bradycardia window, and compare it to the same fraction computed from data in the healthy 213 window, where x is a threshold value plotted along the horizontal axis. We do a similar com-214 parison with the data in the tachycardia window. We compute the fraction of participants 215 with $\Delta RHR \geq x$ computed from the tachycardia window, and compare with the fraction 216 computed from data in the healthy window. Fig. 5 shows this comparison. The curve 217 plotted in red in Fig. 5(a) shows the fraction of individuals in the time window $D_{+7} - D_{+21}$ 218 with $\Delta RHR \leq x$ plotted along the horizontal axis. This should be compared with the curve 219 plotted in green which is an estimate of how likely it is that such a low ΔRHR may occur 220 due to random chance. Fig. 5(b) shows a similar comparison, but for $\Delta RHR \geq x$, and 221 considering the tachycardia window. 222 Interestingly, there is a correlation between the peak value of ΔRHR measured during 223

symptom onset (we use a 15 day window from D_{-5} to D_{+9}) and the peak and minimum

values of Δ RHR measured in the second relative tachycardia window (D_{+22} to D_{+36}) and the




FIG. 6. Correlation between the peak value of Δ RHR measured during symptom onset, and (i) peak value of Δ RHR in the second relative tachycardia window shown in red, (ii) minimum value of Δ RHR measured in the relative bradycardia window shown in blue. The shaded areas represent the 1 standard deviation range.

relative bradycardia window $(D_{+7} \text{ to } D_{+21})$. Fig. 6 shows this correlation. The horizontal 226 axis is ΔRHR during symptom onset, while the vertical axis shows ΔRHR during either the 227 second tachycardia phase (red) or the bradycardia phase (blue). We see that ΔRHR_{tachy} 228 measured in the second relative tachycardia phase is positively correlated with $\Delta RHR_{symptom}$, 229 the peak value observed at symptom onset. Similarly, ΔRHR_{brady} , the minimum value 230 observed during the relative bradycardia phase is positively correlated with $\Delta RHR_{symptom}$. 231 This means that a low ΔRHR at symptom onset is indicative of a decreased RHR in the 232 relative bradycardia phase. An approximate estimate of ΔRHR_{tachy} and ΔRHR_{brady} may 233

be obtained by the following linear relations (with all measurements in bpm):

$$\Delta RHR_{tachy} = 2.27 + 0.468 \Delta RHR_{symptom}$$

$$\Delta RHR_{brady} = -6.67 + 0.622 \Delta RHR_{symptom}.$$
(4)

C. Comparison with other measurements

235




FIG. 7. Excess fractional change in RMSSD and respiratory rate. Subplots (a) and (b) also show the excess fractional change in RHR (dashed black lines). Note that the RHR waveform is smoothed over time, resulting in a more rounded peak. Subplots (c) and (d) show the RMSSD and respiratory rate for male (green) and female (black) subjects respectively.

Let us now briefly consider 2 more health metrics: the heart rate variability quantified by the root mean square of the successive differences (RMSSD) and the respiratory rate.

Fig. 7 shows the excess fractional change $\Delta \xi$ in RMSSD (subplot (a)) and the respiratory 238 rate (subplot (b)), plotted for symptomatic COVID-19. Also shown for comparison in 239 dashed lines is the fractional change in RHR. The fractional change in RMSSD shows a 240 similar time evolution as the RHR, except with opposite phase, i.e. when the RHR is 241 elevated, the RMSSD is decreased and vice-versa. The relative bradycardia phase is seen to be accompanied by elevated heart rate variability, while the second relative tachycardia phase is associated with reduced heart rate variability. The variation is also of greater amplitude with the RMSSD compared to the RHR. The fractional change in the respiratory 245 rate, on the other hand, does not show a similar time evolution. The respiratory rate is 246 elevated during symptom onset, in response to the illness. It then decreases sharply, and 247 then gradually returns to normal. Thus there is no equivalent of the relative bradycardia 248 and second relative tachycardia phases with the respiratory rate. 249

250 IV. DISCUSSION

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

Both COVID-19 and flu cases show 3 distinct phases:

- First relative tachycardia phase during symptom onset when the RHR is elevated above normal, reaching a local peak value A_{t1} at a time T_{t1} days after symptom onset, with a full width at half maximum W_{t1} . The peak value A_{t1} is higher in males compared to females, for COVID-19 (p-value < 0.0001) and flu (p-value = 0.0118).
- Following this peak, the RHR decreases, and reaches a local minimum value $A_{\rm b}$ at a time $T_{\rm b}$ days after symptom onset. If $A_{\rm b} < 0$, we refer to this phase as relative bradycardia, and define a full width at half minimum $W_{\rm b}$. The condition $A_{\rm b} < 0$ is satisfied for females (averaged over all ages), for COVID-19 (p < 0.0001), and for flu (p = 0.042). The condition $A_{\rm b} < 0$ is not statistically significant for males (averaged over all ages), for either COVID-19 or flu.
- Following the minimum, the RHR increases, reaching a second local maximum A_{t2} at a time T_{t2} days from symptom onset, with a full width at half maximum W_{t2} . The peak value A_{t2} is higher in males compared to females, for COVID-19 (p < 0.0001) and flu (p = 0.0667).

Fig. 3 shows $\Delta\xi$ for male and female participants for different cases of COVID-19 severity, and for flu. Since these phases occur with both COVID-19 and flu, they are not novel to COVID-19. They can however, be more prominent in the case of COVID-19. It should be noted that flu has also been associated with cardiovascular disease³⁷. It is also known that the autonomic nervous system plays a key role in sensing and responding to infection, with pathogens activating vagal signaling causing bradyarrhythmias³⁸. It is intriguing that we see a statistically significant difference between male and female individuals, in the time variation of the RHR (Fig. 3) and the time variation of the RMSSD (Fig. 7).

The parameters that describe the time evolution of the RHR depend on sex, age, and disease severity and are tabulated in Tables III, IV and V. They are also plotted in Fig. 4 for different age groups for male and female individuals. The relative bradycardia minimum $A_{\rm b}$ and the time to the minimum $T_{\rm b}$ are correlated with age (The Pearson r for the correlation between $A_{\rm b}$ and age was found to be r=0.80 for females and r=0.97 for males. The Pearson r for the correlation between $T_{\rm b}$ and age was found to be r=0.98 for females and r=0.77 for males). The width of the first relative tachycardia peak $W_{\rm t1}$ is also correlated with age (r=0.83 for females, and r=0.94 for males).

274

275

276

277

278

279

280

281

Among the 3 phases, the relative tachycardia at symptom onset is the easiest to under-282 stand, and may be interpreted as an immune response to infection. More unexpected is 283 the decrease in RHR, possibly resulting in transient relative bradycardia. Approximately 284 1% of individuals experience a value of RHR that is at least 10 bpm lower than normal 285 (see Fig. 5). Sinus bradycardia is known to occur during sleep in the case of COVID-19³⁹. 286 Since Fitbit's measurement of RHR is not the lowest value of heart rate, this raises the 287 possibility that the heart rate during sleep may reach dangerously low values. It is crucial 288 to be aware of this transient relative bradycardia phase, since certain medications used in 289 the treatment of COVID-19 such as Remdesivir have been known to cause bradycardia 40-42. 290 Interestingly, mild cases of COVID-19 are more likely to present with relative bradycardia. 291 It is also more likely to present in females compared to males. A possible explanation for 292 this may be obtained from Fig. 6, and Table I. Fig. 6 shows that the peak RHR during symptom onset is positively correlated with the magnitude of the dip, i.e. a smaller peak RHR during symptom onset is associated with a larger (and possibly negative) dip. It is well 295 known the heart rate is strongly linked to temperature, increasing by 8.5 bpm per 1 degree 296 C increase in temperature, as found in one study⁴³. As seen from Table I, males are more 297

likely to present with a fever compared to females. Similarly, fever is more common in severe 298 cases compared to mild cases. Thus, females as well as mild cases presenting with a small 299 RHR increase (or no increase) are more likely to experience a bradycardia dip compared to 300 males, or severe cases. Similarly, Fig. 6 shows that the peak RHR during symptom onset is 301 positively correlated with the height of the second tachycardia peak. As a result, the second tachycardia peak is higher in males, and for severe cases. The heart rate variability shows a similar time evolution as the resting heart rate, except with opposite phase. Fig. 7 shows 304 the time evolution of the RMSSD (subplot (a)) and the respiratory rate (subplot (b)) with 305 time. Unlike the RMSSD, the respiratory rate decreases monotonously past the initial peak. 306 Subplots (c) and (d) show the variation of RMSSD and respiratory rate, for male and female 307 subjects. 308

There are several limitations to the current work. A major concern is that we do not know 309 whether the individuals who were diagnosed with COVID-19 and flu received medications 310 to treat their illness, and what effects those medications may have had on their heart rate. 311 The symptoms, severity, as well as symptom start date were all obtained from a survey, 312 and could not be independently verified. We have also assumed that the participants were 313 healthy prior to being diagnosed with COVID-19 or flu, and that the control group consisted 314 of healthy individuals. Despite these limitations, the work presented in this article shows how 315 COVID-19 and flu can alter the resting heart rate in the weeks/months following infection. 316 This knowledge can be crucial in the case of patients with cardiac complications, or when 317 patients are being treated with medication known to have cardiac effects.

319 V. CONTRIBUTORS

A.N. and H.W.-S. had access to all the data and verified the results shown. A.N. was responsible for part of the scientific analysis and for preparing the first version of the manuscript. H.W.-S. was responsible for part of the scientific analysis. C.H. led the Fitbit COVID-19 study, and provided valuable insights and feedback on the analysis and presentation of results.

5 VI. DECLARATION OF INTERESTS

All authors are employed by Fitbit Research, Google LLC.

327 VII. DATA SHARING

326

Our consent form and the protocol allow us to make the raw data available to two
academic members of our research consortium, namely Stanford University, and Scripps
Translational Research Institute. Fitbit's privacy policy does not permit us to make the
raw data or aggregate data available to third parties including researchers, outside of our
web API Oauth 2.0 consent process. For specific questions, contact Fitbit at https://
healthsolutions.fitbit.com/contact/.

334 VIII. ACKNOWLEDGMENTS

A.N., H.W.-S. and C.H. acknowledge funding from Fitbit Research, Google LLC. We thank members of the Fitbit Research team for many helpful discussions.

- G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, and B. Cao, "Clinical features of patients infected
- with 2019 novel coronavirus in Wuhan, China," Lancet **395**, 497–506 (2020).
- ³ D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, B. Wang, H. Xiang, Z. Cheng, Y. Xiong,
- Y. Zhao, Y. Li, X. Wang, and Z. Peng, "Clinical Characteristics of 138 Hospitalized Patients
- With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China," JAMA 323, 1061–1069
- (2020).

^{*} anatarajan@google.com

¹ S. Shi, M. Qin, B. Shen, Y. Cai, T. Liu, F. Yang, W. Gong, X. Liu, J. Liang, Q. Zhao, H. Huang,

B. Yang, and C. Huang, "Association of Cardiac Injury With Mortality in Hospitalized Patients

With COVID-19 in Wuhan, China," JAMA Cardiol 5, 802–810 (2020).

² C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng,

T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie,

- ⁴ B. Siripanthong, S. Nazarian, D. Muser, R. Deo, P. Santangeli, M. Y. Khanji, L. T. Cooper, and
- ³⁵⁰ C. A. A. Chahal, "Recognizing COVID-19-related myocarditis: The possible pathophysiology
- and proposed guideline for diagnosis and management," Heart Rhythm 17, 1463–1471 (2020).
- ⁵ E. J. Coromilas, S. Kochav, I. Goldenthal, A. Biviano, H. Garan, S. Goldbarg, J. H. Kim,
- I. Yeo, C. Tracy, S. Ayanian, J. Akar, A. Singh, S. Jain, L. Zimerman, M. Pimentel, S. Osswald,
- R. Twerenbold, N. Schaerli, L. Crotti, D. Fabbri, G. Parati, Y. Li, F. Atienza, E. Zatarain,
- G. Tse, K. S. K. Leung, M. E. Guevara-Valdivia, C. A. Rivera-Santiago, K. Soejima, P. De Fil-
- ippo, P. Ferrari, G. Malanchini, P. Kanagaratnam, S. Khawaja, G. W. Mikhail, M. Scanavacca,
- L. Abrahão Hajjar, B. Rizerio, L. Sacilotto, R. Mollazadeh, M. Eslami, V. Laleh Far, A. V.
- Mattioli, G. Boriani, F. Migliore, A. Cipriani, F. Donato, P. Compagnucci, M. Casella,
- A. Dello Russo, J. Coromilas, A. Aboyme, C. G. O'Brien, F. Rodriguez, P. J. Wang, A. Nani-
- wadekar, M. Moey, C. S. Kow, W. K. Cheah, A. Auricchio, G. Conte, J. Hwang, S. Han,
- P. E. Lazzerini, F. Franchi, A. Santoro, P. L. Capecchi, J. A. Joglar, A. G. Rosenblatt,
- M. Zardini, S. Bricoli, R. Bonura, J. Echarte-Morales, T. Benito-González, C. Minguito-Carazo,
- F. Fernández-Vázquez, and E. Y. Wan, "Worldwide Survey of COVID-19-Associated Arrhyth-
- mias," Circ Arrhythm Electrophysiol 14, e009458 (2021).
- ⁶ A. N. Kochi, A. P. Tagliari, G. B. Forleo, G. M. Fassini, and C. Tondo, "Cardiac and arrhythmic
- complications in patients with COVID-19," J Cardiovasc Electrophysiol **31**, 1003–1008 (2020).
- ⁷ B. Long, W. J. Brady, A. Kovfman, and M. Gottlieb, "Cardiovascular complications in COVID-
- ³⁶⁸ 19," Am J Emerg Med **38**, 1504–1507 (2020).
- ⁸ A. Y. Cizgici, H. Zencirkiran Agus, and M. Yildiz, "COVID-19 myopericarditis: It should be
- kept in mind in today's conditions," Am J Emerg Med 38, 5–1547 (2020).
- ⁹ M. Linschoten, S. Peters, M. van Smeden, L. S. Jewbali, J. Schaap, H. M. Siebelink, P. C.
- Smits, R. G. Tieleman, P. van der Harst, W. H. van Gilst, and F. W. Asselbergs, "Cardiac
- complications in patients hospitalised with COVID-19," Eur Heart J Acute Cardiovasc Care 9,
- 374 817–823 (2020).
- ³⁷⁵ M. Sahranavard, A. Akhavan Rezayat, M. Zamiri Bidary, A. Omranzadeh, F. Rohani,
- R. Hamidi Farahani, E. Hazrati, S. H. Mousavi, M. Afshar Ardalan, S. Soleiman-Meigooni,
- S. J. Hosseini-Shokouh, Z. Hejripour, E. Nassireslami, R. Laripour, A. Salarian, A. Nourmo-
- hammadi, and R. Mosaed, "Cardiac Complications in COVID-19: A Systematic Review and
- ³⁷⁹ Meta-analysis," Arch Iran Med **24**, 152–163 (2021).

- 380 11
- 12 G. Capoferri, M. Osthoff, A. Egli, M. Stoeckle, $\,$ and S. Bassetti, "Relative bradycardia in
- patients with COVID-19," Clin Microbiol Infect 27, 295–296 (2021).
- ¹³ S. Douedi, A. Mararenko, A. Alshami, M. Al-Azzawi, F. Ajam, S. Patel, H. Douedi, and
- D. Calderon, "COVID-19 induced bradyarrhythmia and relative bradycardia: An overview," J
- 385 Arrhythm **37**, 888–892 (2021).
- ¹⁴ A. Oliva, C. Franchi, M. C. Gatto, G. Galardo, F. Pugliese, and C. Mastroianni, "Prevalence
- and clinical significance of relative bradycardia at hospital admission in patients with coron-
- avirus disease 2019 (COVID-19)," Clin Microbiol Infect **27**, 1185–1187 (2021).
- E. A. Amaratunga, D. S. Corwin, L. Moran, and R. Snyder, "Bradycardia in Patients With
- 390 COVID-19: A Calm Before the Storm?" Cureus **12**, e8599 (2020).
- ¹⁶ M. Amir, H. Yoseph, A. T. A. Farisi, J. K. P. Phie, and A. T. S. Adam, "Symptomatic
- Bradycardia in Covid-19 Hospitalized Patients: A Case Series," Int J Infect Dis 111, 1–4
- 393 (2021).
- ¹⁷ W. Elikowski, N. Fertala, M. Zawodna-Marszalek, J. Rajewska-Tabor, W. Swidurski, D. Wa-
- idlich, A. Marszalek, P. Skrzywanek, M. Pyda, and M. Zytkiewicz, "Marked self-limiting sinus
- bradycardia in COVID-19 patients not requiring therapy in the intensive care unit case series
- report," Pol Merkur Lekarski **49**, 295–302 (2021).
- ¹⁸ A. Srinivasan, T. Pansuriya, B. Wilson, S. T. Sarva, T. Javaram, S. Alim, R. Kesavan, and
- S. Raza, "Systemic Inflammation-Related Bradycardia in COVID-19," Case Rep Cardiol 2021,
- 9986955 (2021).
- ⁴⁰¹ M. Zhou, C. K. Wong, K. C. Un, Y. M. Lau, J. C. Lee, F. C. Tam, Y. M. Lau, W. H. Lai,
- A. R. Tam, Y. Y. Lam, P. Pang, T. Tong, M. Tang, H. F. Tse, D. Ho, M. Y. Ng, E. W. Chan,
- I. C. K. Wong, C. P. Lau, I. F. Hung, and C. W. Siu, "Cardiovascular sequalae in uncomplicated
- 404 COVID-19 survivors," PLoS One **16**, e0246732 (2021).
- ²⁰ T. Guo, Y. Fan, M. Chen, X. Wu, L. Zhang, T. He, H. Wang, J. Wan, X. Wang, and Z. Lu,
- "Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019
- (COVID-19)," JAMA Cardiol 5, 811–818 (2020).
- ²¹ A. Bhatla, M. M. Mayer, S. Adusumalli, M. C. Hyman, E. Oh, A. Tierney, J. Moss, A. A.
- Chahal, G. Anesi, S. Denduluri, C. M. Domenico, J. Arkles, B. S. Abella, J. R. Bullinga, D. J.
- Callans, S. Dixit, A. E. Epstein, D. S. Frankel, F. C. Garcia, R. Kumareswaram, S. Nazarian,

- M. P. Riley, P. Santangeli, R. D. Schaller, G. E. Supple, D. Lin, F. Marchlinski, and R. Deo,
- "COVID-19 and cardiac arrhythmias," Heart Rhythm 17, 1439–1444 (2020).
- ²² P. Dherange, J. Lang, P. Qian, B. Oberfeld, W. H. Sauer, B. Koplan, and U. Tedrow, "Ar-
- rhythmias and COVID-19: A Review," JACC Clin Electrophysiol 6, 1193–1204 (2020).
- ²³ G. Peigh, M. V. Leya, J. R. Baman, E. P. Cantey, B. P. Knight, and J. D. Flaherty, "Novel
- coronavirus 19 (COVID-19) associated sinus node dysfunction: a case series," Eur Heart J Case
- Rep **4**, 1–6 (2020).
- ²⁴ D. J. Miller, J. V. Capodilupo, M. Lastella, C. Sargent, G. D. Roach, V. H. Lee, and E. R.
- Capodilupo, "Analyzing changes in respiratory rate to predict the risk of COVID-19 infection,"
- PLoS One **15**, e0243693 (2020).
- ²⁵ T. Mishra, M. Wang, A. A. Metwally, G. K. Bogu, A. W. Brooks, A. Bahmani, A. Alavi, A. Celli,
- E. Higgs, O. Dagan-Rosenfeld, B. Fay, S. Kirkpatrick, R. Kellogg, M. Gibson, T. Wang, E. M.
- Hunting, P. Mamic, A. B. Ganz, B. Rolnik, X. Li, and M. P. Snyder, "Pre-symptomatic
- detection of COVID-19 from smartwatch data," Nat Biomed Eng 4, 1208–1220 (2020).
- ²⁶ G. Quer, J. M. Radin, M. Gadaleta, K. Baca-Motes, L. Ariniello, E. Ramos, V. Kheterpal, E. J.
- Topol, and S. R. Steinhubl, "Wearable sensor data and self-reported symptoms for COVID-19
- detection," Nat Med **27**, 73–77 (2021).
- ²⁷ A. Natarajan, H. W. Su, and C. Heneghan, "Assessment of physiological signs associated with
- 429 COVID-19 measured using wearable devices." NPJ Digit Med 3, 156 (2020).
- ⁴³⁰ A. Natarajan, H. W. Su, C. Heneghan, L. Blunt, C. O'Connor, and L. Niehaus, "Measurement
- of respiratory rate using wearable devices and applications to COVID-19 detection," NPJ Digit
- 432 Med **4**, 136 (2021).
- ⁴³³ J. C. Miller, D. Skoll, and L. A. Saxon, "Home Monitoring of Cardiac Devices in the Era of
- 434 COVID-19," Curr Cardiol Rep **23**, 1 (2020).
- ³⁰ J. M. Radin, G. Quer, E. Ramos, K. Baca-Motes, M. Gadaleta, E. J. Topol, and S. R. Steinhubl,
- "Assessment of Prolonged Physiological and Behavioral Changes Associated With COVID-19
- Infection," JAMA Netw Open 4, e2115959 (2021).
- ⁴³⁸ Y. Ostchega, K. S. Porter, J. Hughes, C. F. Dillon, and T. Nwankwo, "Resting pulse rate
- reference data for children, adolescents, and adults: United States, 1999-2008," Natl Health
- Stat Report, 1–16 (2011).

- ⁴²¹ A. Russell, C. Heneghan, and S. Venkatraman, "Investigation of an estimate of daily rest-
- ing heart rate using a consumer wearable device," medRxiv (2019), 10.1101/19008771,
- https://www.medrxiv.org/content/early/2019/10/18/19008771.full.pdf.
- ³³ G. Quer, P. Gouda, M. Galarnyk, E. J. Topol, and S. R. Steinhubl, "Inter- and intraindividual
- variability in daily resting heart rate and its associations with age, sex, sleep, BMI, and time
- of year: Retrospective, longitudinal cohort study of 92,457 adults," PLoS One 15, e0227709
- 447 (2020).
- ³⁴ R. G. Miller, "The jackknife-a review," Biometrika **61**, 1-15 (1974).
- B. Efron, "Nonparametric estimates of standard error: The jackknife, the bootstrap and other
- methods," Biometrika **68**, 589–599 (1981).
- ³⁶ A. Natarajan, A. Pantelopoulos, H. Emir-Farinas, and P. Natarajan, "Heart rate variability
- with photoplethysmography in 8 million individuals: a cross-sectional study," Lancet Digit
- Health 2, e650–e657 (2020).
- ⁴⁵⁴ J. L. Nguyen, W. Yang, K. Ito, T. D. Matte, J. Shaman, and P. L. Kinney, "Seasonal Influenza
- Infections and Cardiovascular Disease Mortality," JAMA Cardiol 1, 274–281 (2016).
- 456 38 K. D. Fairchild, V. Srinivasan, J. R. Moorman, R. P. Gaykema, and L. E. Goehler, "Pathogen-
- induced heart rate changes associated with cholinergic nervous system activation," Am J Physiol
- Regul Integr Comp Physiol **300**, R330–339 (2011).
- 459 39 L. Hu, L. Gong, Z. Jiang, Q. Wang, Y. Zou, and L. Zhu, "Clinical analysis of sinus bradycardia
- in patients with severe COVID-19 pneumonia," Crit Care 24, 257 (2020).
- ⁴⁰ A. K. Gupta, B. M. Parker, V. Priyadarshi, and J. Parker, "Cardiac Adverse Events With
- Remdesivir in COVID-19 Infection," Cureus 12, e11132 (2020).
- 463 41 M. I. Sanchez-Codez, M. Rodriguez-Gonzalez, and I. Gutierrez-Rosa, "Severe sinus bradycardia
- associated with Remdesivir in a child with severe SARS-CoV-2 infection," Eur J Pediatr 180,
- 465 1627 (2021).
- ⁴⁶⁶ J. P. Jacinto, M. Patel, J. Goh, and K. Yamamura, "Remdesivir-induced symptomatic brady-
- cardia in the treatment of COVID-19 disease." HeartRhythm Case Rep 7, 514-517 (2021).
- ⁴³ J. Karjalainen and M. Viitasalo, "Fever and cardiac rhythm," Arch Intern Med **146**, 1169–1171
- 469 (1986).